Company intelligence / Profile preview
IOZK
Cologne, North Rhine-Westphalia, Germanyiozk.de ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
IOZK offers individualized immunotherapies for cancer patients, primarily combining autologous dendritic cell vaccines with Newcastle Disease Virus vaccine. They have also begun incorporating immune checkpoint inhibitors into their regimens. Their approach is designed to activate the patient’s own immune system against tumor cells, aiming to improve quality of life and potentially influence disease course positively. Complete cures are rare for advanced tumors, but the therapies may provide benefit in disease control and symptom management[1][2].
- Therapeutic areas
- Oncology
- Modalities
- Dendritic cell therapyOncolytic virus therapy (Newcastle Disease Virus vaccine)Immune checkpoint inhibitor therapy (incorporated into protocols)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on IOZK.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IOZK.